Evidence map›Paper›PMID 37006377›Full record

ArticleJournal of Alzheimer's disease & Parkinsonism2022

Parkinson's Disease Blood Test for Primary Care.

Sid E O'Bryant, Melissa Petersen, Fan Zhang, Leigh Johnson, Dwight German, James Hall

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Journal of Alzheimer's disease & Parkinsonism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sid E O'BryantDepartment of Neuroscience and Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Melissa PetersenDepartment of Neuroscience and Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Fan ZhangDepartment of Neuroscience and Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Leigh JohnsonDepartment of Neuroscience and Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.
Dwight GermanDepartment of Psychiatry, UT Southwestern Medical School, Dallas, Texas, USA.
James HallDepartment of Neuroscience and Pharmacology, University of North Texas Health Science Center, Fort Worth, Texas, USA.

Funding

Health Disparities in Alzheimer's Disease and Mild Cognitive Impairment among Mexican AmericansR01AG054073 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, TOGA, ARTHUR W · 2017 to 2021
$12.6M
An Alzheimer's Blood Test for Primary CareR01AG058537 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI O'BRYANT, SID E, YAFFE, KRISTINE · 2018 to 2020
$6.5M
Diagnostic and prognostic biomarkers for Parkinsons diseaseU01NS082148 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI DEWEY, RICHARD B, GERMAN, DWIGHT C. · 2012 to 2016
$3.0M
NIA NIH HHS R01 AG054073NIA NIH HHS R01 AG058537NINDS NIH HHS U01 NS082148
6 · The paper itself

Abstract

Background: A blood-test that could serve as a potential first step in a multi-tiered neurodiagnostic process for ruling out Parkinson's disease (PD) in primary care settings would be of tremendous value. This study therefore sought to conduct a large-scale cross-validation of our Parkinson's disease Blood Test (PDBT) for use in primary care settings. Methods: Serum samples were analyzed from 846 PD and 2291 volunteer controls. Proteomic assays were run on a multiplex biomarker assay platform using Electrochemiluminescence (ECL). Diagnostic accuracy statistics were generated using area under the receiver operating characteristic curve (AUC), Sensitivity (SN), Specificity (SP) and Negative Predictive Value (NPV). Results: In the training set, the PDBT reached an AUC of 0.98 when distinguishing PD cases from controls with a SN of 0.84 and SP of 0.98. When applied to the test set, the PDBT yielded an AUC of 0.96, SN of 0.79 and SP of 0.97. The PDBT obtained a negative predictive value of 99% for a 2% base rate. Conclusion: The PDBT was highly successful in discriminating PD patients from control cases and has great potential for providing primary care providers with a rapid, scalable and cost-effective tool for screening out PD.

Indexed as

Blood testParkinson’s diseasePrimary careScreening toolSerum

Identifiers

PMID37006377
PMCPMC10065753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.